Table. 1 Demographic data of AML patients with their cytogenetic abnormalities and genetic lesions classified by functions.
Sample | Sex | Age (years) | Karyotype | Genetic lesions | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
Signaling genes | DNA methylation-related genes | Chromatin-modifying genes | Nucleophosmin gene | Cohesin complex genes | Spliceosome complex genes | Transcription factor fusions | ||||
An investigation of the effect of fadraciclib on primary AML cells harboring KMT2A-PTD or KMT2A WT | ||||||||||
AML 22 | M | 68 | Normal | FLT3-ITD | DNMT3A, TET2 | KMT2A-PTD | SRSF2 | RUNX1 | ||
AML 20B | M | 80 | NA | KMT2A-PTD | U2AF1 | |||||
AML H002 | NA | NA | Normal | IDH2 | KMT2A-PTD, ASXL1 | |||||
AML 12 | F | 65 | Normal | DNMT3A | KMT2A-PTD | |||||
AML 17 | M | 72 | Trisomy 21 | NRAS | KMT2A-PTD, ASXL1 | NPM1 | U2F1 | |||
AML 18 | M | 68 | Normal | NRAS | TET2 | ASXL1, EZH2 | ||||
AML 13 | F | 43 | Normal | FLT3-ITD | NPM1 | |||||
AML 44 | M | 79 | Monosomy 7 | FLT3-ITD | DNMT3A, IDH2 | |||||
AML 5 | M | 46 | Trisomy 8 t(15;17) | TET2 | ASXL1 | SRSF2 | ||||
AML 36 | M | 78 | Trisomy 11 | DNMT3A, IDH1 | STAG2 | SRSF2 | ||||
Drug combination studies | ||||||||||
AML H002 | NA | NA | Normal | IDH2 | KMT2A-PTD, ASXL1 | |||||
AML 44 | M | 79 | Monosomy 7 | FLT3-ITD | DNMT3A, IDH2 | |||||
AML 52 | M | 73 | Normal | FLT3-ITD | DNMT3 | NPM1 | RAD21 | |||
AML 31 | F | 56 | Complex | KIT | NPM1 | |||||
AML 36 | M | 78 | Trisomy 11 | DNMT3A, IDH1 | STAG2 | SRSF2 | ||||
AML 22 | M | 68 | Normal | FLT3-ITD | DNMT3A TET2 | KMT2A-PTD | SRSF2 | RUNX1 | ||
